Satellos Bioscience (TSXV: MSCL, OTC: MSCLF, FRA: 0ITA) is a bioscience company focused on providing a game-changing solution named MyoReGenXTM that would restore the body’s natural capacity. The company shared on March 10 other outstanding results, always bringing them closer to healing Duchenne Muscular Dystrophy as no proven solutions exist. 

‍

‍

What is the Duchenne Muscular Dystrophy? 

‍

Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a dystrophin protein that helps keep muscle cells intact. The main sign of DMD is muscle weakness. It can start as early as 2 or 3 years old, initially affecting the proximal muscles (those closest to the body's center) before progressing to the distal limb muscles (those close to the extremities). The lower external muscles typically experience pain before the upper external muscles. The impacted child may have trouble running, walking, and leaping. Additional signs include lumbar lordosis, swelling of the calves, and a waddling gait (an inward curve of the spine). Subsequently, the respiratory and cardiac muscles are also impacted. Scoliosis and progressive weakening lead to pulmonary function impairment, which can eventually lead to acute respiratory failure.

‍

Company Overview

‍

Satellos Bioscience (TSXV: MSCL, OTC: MSCLF, FRA: 0ITA) is a biotechnology company founded on game-changing science in skeletal muscle regeneration. The goal is to create and develop drugs that restore the body's natural capacity for self-healing as an innovative method of treating debilitating muscle problems. By utilizing the exclusive MyoReGenXTM research platform, Satellos has made a number of additional discoveries in regulating these cells and has uncovered regeneration impairments ranging from age-related disabilities to genetic illnesses like Duchenne muscular dystrophy. The company's flagship therapeutic program in Duchenne, where they have demonstrated that defective stem cell activity substantially impairs muscle regeneration throughout life, aims to address this stem cell insufficiency to enable muscle regeneration. To address the increasing muscle loss associated with Duchenne and other severe illnesses, Satellos believes its new therapy strategy offers promise for extending and improving patient lives.

‍

MyoReGenXTM 

‍

MyoReGenX™ was designed to recreate the specialized muscle stem cell niche in vitro. The identity and function of muscle stem cells outside the body must be sustained by maintaining this microenvironment, a sine qua non. Satellos can map the pathways that affect muscle repair and regeneration, identify and validate drug targets, and test drug candidates for their capacity to restore muscle stem cell repair mechanisms hampered by genetic mutations, illness, or injury, which gives MyoReGenXTM a distinct advantage.  MyoReGenXTM is being used by Satellos to create revolutionary muscle stem cell-targeted regenerative medicines that have the potential to enhance the lives of people with critical muscular illnesses significantly. Muscular dystrophies and aging muscles are our initial research emphasis areas.

‍

Breaking News

‍

On March 10, the company released more findings from additional preclinical tests utilizing its primary medication candidate, SAT-3153. After one week, SAT-3153-treated Mdx mice showed a statistically significant difference in polarity by creating new progenitor muscle cells compared to placebo-treated controls (n=5 per group) in a study that tested the drug's quick mechanism of action in an acute injury paradigm. In an additional in vivo experiment, Mdx mice received SAT-3153 four times per week compared to placebo controls (n=8) displayed a 19% increase in muscle force after two weeks. Further preclinical research has revealed that SAT-3153 has oral bioavailability, a plasma protein binding level of 90%, no hERG channel binding (a crucial criteria to rule out potential cardiac toxicity), and no binding of the hERG channel.

‍

"It is so gratifying to see that we have our own proprietary drug with the potential to reset the body's innate regenerative ability in skeletal muscle. It has been our dream to develop a small molecule that could help people living with Duchenne regardless of their exon mutation status, level of background AAV antibodies, or ambulatory status. We are one step closer to making that dream a reality."

Dr. Michael Rudnicki, the Company's co-founder and Chief Scientific Officer

‍

‍

Share Structure / Financials 

‍

For the last quarter ending September 30, 2022, the company had solid cash and cash equivalents of $3M, $10.2M in total assets, for $2M in total liabilities. Satellos endured a $1.89M loss, where $544k was directly put into research and development contracting. 

About the share structure, we can definitely say this data is low. 41.7M shares are issued, and outstanding, 1.4M options at $1.28, and 5.2M warrants at $0.63 are available. The company currently can exercise neither of them because the stock price is under exercise prices. Insiders hold a solid ratio of the share structure as they detain 27% of it. 

Since mid-September 2022, the stock price has been relatively steady, hovering between $0.22 (52-week low) and $0.42. Besides, the 52-week high is worth $1.2 and was reached on April 25, 2022. 

‍

Conclusion

‍

Satellos Bioscience (TSXV: MSCL, OTC: MSCLF, FRA: 0ITA) still has a long way to go, but news shared on March 10 indicates the company is in the right direction. Satellos also boasts a solid balance sheet combined with a low and robust share structure (insiders hold 27%). 

‍